Kisqali (ribociclib) is approved to treat HR-positive and HER2-negative breast cancer in adults, along with an aromatase inhibitor drug or fulvestrant (Faslodex). It also comes packaged in a ...
Patritumab deruxtecan, with or without letrozole, showed similar efficacy to chemotherapy in high-risk HR-positive, HER2-negative breast cancer, with lower severe side effects. The SOLTI VALENTINE ...
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results